Background. Induction of immune tolerance by an increase in regulatory T (Treg) cells after extracorporeal photopheresis (ECP) is thought to contribute to how ECP exerts its therapeutic effect in patients with chronic graft-versus-host disease (cGvHD). We investigated whether percentages and absolute counts of Treg cells changed post-ECP, and examined correlation with response. Methods. Absolute counts and % of CD4+ T cells and Treg cells (CD4 + CD25 + FOXP3 + CD127dim/−) were evaluated using flow cytometry in 32 patients with cGvHD treated by ECP for a minimum of 3 months, and up to 12 months. CD4+ or Treg cells at baseline to 12 months post-ECP were compared with changes in skin disease scores or global organ involvement, or the ability to taper steroids, at 14, 28, and 56 weeks. Results. Regulatory Tcells % increased significantly above any overall changes in CD4+ % at 6, 9, and 12 months post-ECP. There was no statistically significant association between Treg cells and skin or steroid response, whereas a larger increase in CD4+ count from baseline to 1 to 3 months corresponded to increased odds of being able to reduce steroid dose by 50% or greater at 14 weeks. Skin and global organ responders at 28 weeks had higher median Treg cell counts 3 months post-ECP than nonresponders, as did steroid responders at 56 weeks who were 12 months post-ECP. Conclusions. Regulatory T cell counts and % varied greatly among cGvHD patients, and the increase post-ECP was not significant until 6 months. No clear correlation was found between Treg cells and clinical improvement, suggesting that increases in Treg cell numbers and/or proportions are not driving the mechanism leading to a response after ECP.
C hronic graft-versus-host disease (cGvHD) is an immunological disorder that remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). It involves alloreactivity of donor T cells to host histocompatibility antigens, which can affect many sites, such as the skin, mucous membranes, liver, and lungs. Corticosteroids and immunosuppressive drugs are common treatments for cGvHD, but the resulting unpredictable and variable response rates, toxicities, and profound immunodeficiency can cause deaths from infection. Extracorporeal photopheresis (ECP) is used as a safe and efficacious treatment for some immune-mediated diseases, such as steroid-refractory cGvHD, following on from its development in 1987 for use in treating cutaneous T-cell lymphoma. Clinical improvement in cGvHD patients treated with ECP enables tapering or discontinuation of immunosuppressive agents and corticosteroids. Because T-and B-cell responses to novel and recall antigens are not destroyed by ECP, it brings a reduced risk of infection compared with the use of immunosuppressive drugs. 1 Extracorporeal photopheresis is an apheresis therapy that involves centrifugal separation and collection of white blood cells (WBC) from blood, with the return of red blood cells and plasma to the patient. The photosensitising agent, 8-methoxypsoralen, is administered to the collected WBC, followed by circulation through an irradiation chamber, where exposure to ultraviolet-A radiation occurs. The photoactivated 8-methoxypsoralen causes cross-linking of DNA in cell nuclei, inducing apoptosis of the treated WBC, which are then reinfused to the patient. Apoptotic cells express specific membrane proteins that are recognized by receptors on antigen-presenting cells in the circulation. The full effects of ECP on the immune system remain poorly understood, but it is thought that returning apoptosing WBC to the patient induces immune tolerance by modulating antigen-presenting cells, switching their activity in favor of antiinflammatory cytokine production while decreasing production of proinflammatory cytokines and inducing regulatory T (Treg) cell. 2 Regulatory T cells are a subpopulation of T cells that can derive from the thymus (natural Treg cell) or be induced in peripheral lymphoid organs (induced Treg cell). 3 Regulatory T cells can suppress effector T cell responses and the activity of other immune cells, such as dendritic and B cells. The balance between effector T cell and Treg cell populations is critical in achieving proper control of the quality and extent of adaptive immune responses, for establishing self-tolerance, and intolerance to nonself antigens. Regulatory T cells are CD4+ cells that express high levels of CD25 (the IL-2 receptor α-chain) and the transcription factor, forkhead box protein-3 (FOXP3). Forkhead box protein-3 is a key regulator of Treg cell development and function. Nonregulatory T cells can also express the intracellular marker FOXP3, so a more stringent definition of Treg cells incorporates an additional marker of high specificity. Regulatory T cells downregulate expression of the IL-7 receptor α-chain (CD127) compared with conventional T cells, so a CD127dim/− marker is also often used for Treg cell characterization. 4 The ability of Treg cells to suppress aberrant immune responses, regulate T cell homeostasis, and to maintain selftolerance, prompted interest in their impact on cGvHD, and how ECP might influence their numbers. 5 Evidence that Treg cells play a key role in GvHD was demonstrated in a mouse model where removal of the CD4 + CD25+ T cells present in the stem cell graft accelerated GvHD, and adding freshly isolated CD4 + CD25+ T cells at the time of HSCT delayed, or even prevented, this disease. 6 Administration of cultured and activated CD4 + CD25+ Treg cells was shown to inhibit GvHD lethality in mice. 7 Striking results in murine GvHD, coupled with the ready availability of donor Treg cells, has led to GvHD prevention emerging as the first clinical application for human Treg cell. 8 Evidence for treating existing GvHD with Treg cells remains sparse; however, an anecdotal report suggested that amelioration of cGvHD in 1 patient after transfer of in vitro expanded donor Treg cells. 9 The potential impact of Treg cells in ECP was observed when established experimental GvHD was reversed in mice by increasing donor Treg cells as a consequence of transferring splenocytes from ECP-treated animals. 10 Regulatory T cells whose development is promoted during ECP are antigen-specific, corresponding to the clones of cytotoxic T cells that were collected in the apoptotic WBC product after predominating in the circulation during an active immune response.
2 Using a hypersensitivity model in mice, Maeda and colleagues 11 showed that antigen-specific Treg cells were induced by apoptotic cells generated from ECP, and that transferring these Treg cells to other syngeneic mice created the same antigen-specific immune suppression.
Despite frequent suggestions that Treg cells play an integral part in the mode of action of ECP when used to treat cGvHD patients, reported levels of Treg cells in this disease remain inconclusive. Compared with HSCT recipients without cGvHD, both an increase, 12, 13 and a decrease, 14, 15 in Treg cells have been documented in cGvHD. A study of 29 HSCT patients reported that a numerical deficit of Treg cells after HSCT was associated with acute, but not chronic, GvHD, 16 whereas a different study reported elevated Treg cell numbers and percentages in both acute and chronic GvHD. 17 There is a paucity of studies reporting the effects of ECP on Treg cell numbers and proportions in cGvHD patients. We performed a study of 32 patients, using flow cytometry to determine changes in CD4+ T cell and Treg cell numbers and proportions after a minimum of 3 months ECP treatment, and examined how these cell measures correlated with skin and global organ responses, and the ability to taper steroids. Here, we report that Treg cell numbers increase statistically significantly post-ECP above any overall change in CD4+ T cells, and that these Treg cell increases are not a universal feature of response to ECP. This is the largest study to date that comprehensively examines the effect of ECP on Treg cell numbers and their association with clinical improvement in cGvHD patients.
MATERIALS AND METHODS

Study Population
Adult patients (n = 32; 50% men, aged 19-62 years; median, 46.5 years) diagnosed with cGvHD provided written consent and were included in the study, subject to the inclusion and exclusion criteria detailed in Table 1 . At ECP start, 78% of patients had skin involvement, and 91% were on steroids. Patient characteristics are detailed in Table 1 . Extracorporeal photopheresis was performed using the THERAKOS, CELLEX, or UVAR XTS Photopheresis Systems at the Photopheresis Unit, Rotherham NHS Foundation Trust. Patients received 2 treatments over 2 consecutive days (1 cycle) every fortnight for 14 weeks, then 1 cycle every 4 weeks, although some variation did occur (see Table 1 ). The study period was 56 weeks: all 32 patients were treated for a minimum of 3 months; 28 for 6 months or longer; 26 for 9 months or longer; and 26 patients were treated for 12 months or longer. Reasons for stopping ECP in the 6 patients that received ECP for less than 12 months include death from infections (n = 4), an unscheduled stop (n = 1) and cGvHD improvement (maximal response) (n = 1). Peripheral blood (PB) samples were taken every month immediately before each treatment cycle commenced. Peripheral blood was also collected from 25 agematched healthy volunteers, who gave informed consent, to enable comparison with patient CD4+ T-cell counts and %. The study was approved by York Research Ethics Committee, and internally by the R&D Department.
Measures of Response to ECP
Clinical response scores were obtained at 14, 28, and 56 weeks post-ECP, where possible. Skin: The modified Rodnan scoring system was used to evaluate skin disease, where a high score equates to more severe skin disease and the % reduction in skin score from baseline was used to calculate response. Patients with a 0% to 24% reduction in skin score were classed as nonresponders, whereas responders experienced a 25% to 100% reduction from pre-ECP values. Steroids: The ability to reduce steroid dose (mg/kg) by 50% or greater, while disease activity was controlled or improved by ECP, was considered a response. Patients whose steroids were tapered only 0% to 49%, or received an increased dose, were considered nonresponders. Global organ: Global organ response was derived based on changes in the level of involvement of the main organ affected (skin, gut, liver, eyes, mucous membranes, or lung), using the response definition detailed above for skin, and the 2005 National Institutes of Health cGvHD Consensus Response Criteria 18 for all other organs. For our analyses, either a partial or complete response, as detailed by the National Institutes of Health response definitions, were considered to be a global organ response. Nonresponders were defined according to the criteria for organ progression. 
Flow Cytometry of CD4+ Cells and Treg Cells
Fresh anticoagulated PB samples were used for enumeration of CD4+ T cells. CD4+ T cells were identified after incubation of 100 μL PB at 4°C for 30 minutes with antihuman antibodies as follows: CD4 conjugated with phycoerythrincyanine 7 (PE-Cy7), PE-Texas Red (energy-coupled dye)-conjugated CD45, and CD3-PE antihuman antibodies. All antibodies were from Beckman Coulter (BC) (Buckinghamshire, UK), except CD4-PE-Cy7 (BD Biosciences, Oxford, UK). Red blood cells were lysed with IOTest 3 Lysing Solution (BC) after antibody staining of WBC.
For enumeration of Treg cells, intracellular labeling was required. Mononuclear cells were first separated from fresh PB samples using LymphoPrep density gradient medium (AxisShield PoC AS, Norway), according to the manufacturer's recommendation, and washed 2 times with RPMI-1640 medium (Sigma-Aldrich, Dorset, UK). Cells were labeled for cell surface markers by incubating 100 μL cell preparation at 4°C for 30 minutes with antihuman antibodies: CD127 conjugated with fluorescein isothiocyanate (BD Pharmingen, Oxford, UK), CD25-PE-Cy5 (BC), CD4-PE-Cy7, and CD45-energy-coupled dye. Labeled cells were subsequently washed with cold 0.9% NaCl solution, fixed, and permeabilized using a kit (Miltenyi, Surrey, UK) according to the manufacturer's protocol, and intracellular staining performed using an antihuman FOXP3-PE antibody (Miltenyi). Cells were resuspended in 500 μL 0.9% NaCl solution before analysis.
Regulatory T cells were identified by the phenotypic expression profile CD4 + CD25 + FOXP3 + CD127dim/−. The frequencies (%) of lymphocytes that were CD3 + CD4+, and the % of CD3 + CD4+ T cells that were Treg cells were evaluated using 5-color flow cytometry on an FC-500 Flow Cytometer (BC), after gating of lymphocytes according to CD45 expression and side-scatter. Absolute counts (cells/μL) of CD3 + CD4+ T cells were calculated by multiplying their % by the lymphocyte count, obtained by automated differential using an Advia 2120i Haematology System (Siemens, Germany). Regulatory T cell counts were derived by multiplying their % by the count of CD3 + CD4+ T cells.
Statistical Analysis
All analyses were performed using SPSS software version 20 (IBM Corp., Armonk, NY). Multiple analyses (Materials and Methods, SDC, http://links.lww.com/TP/B255) were performed to address the following questions:
-Are there statistically significant differences in: 
RESULTS
Response Rates of the Study Group
To establish whether our patient cohort gave results that were representative of previously established response rates, we examined the skin, steroid, and global organ response at the last measured time point (≤12 months) for each patient. 4 (12.5%) patients had died by 8 months of commencing ECP. Of the 26 patients that had skin involvement, 65.4% undergoing ECP achieved at least a 25% improvement in skin scores. Similarly, 60% of the 30 patients on steroids demonstrated a response to ECP, where a 50% or greater dose reduction was achieved. Global organ responders accounted for 71.9% of the 32 patients in our cohort. Our response rates were comparable to the study of 32 cGvHD patients by Apisarnthanarax et al, 19 who found 64% achieved a 50% or greater steroid dose reduction, and to a study by Couriel et al 20 of 71 patients with severe cGvHD, where overall improvement was seen in 61%, with 59% of patients achieving a skin response.
Prior Acute GvHD
No statistically significant differences were found in Treg cell or CD4+ measures between patients that had acute GvHD before their cGvHD and those that did not.
Differences in CD4+ Measures Between cGvHD Patients and Healthy Controls
Patients with cGvHD had statistically significantly lower CD4+ % and counts at baseline (P < 0.001) and at the last measured time point post-ECP (P < 0.001), than the healthy control group.
Changes in the Proportion of Treg Cell/CD4+ Cells With ECP Treatment Duration
After accounting for overall changes in CD4+ measures, there was a statistically significant increase in Treg cell measures over time (P = 0.01). Compared with pre-ECP measures, there were statistically significant increases of Treg cell proportions at 6 months (P = 0.003), 9 months (P = 0.008), and 12 months (P = 0.02). Median Treg cell count increased 3.7-fold at 9 months from the pre-ECP value. No statistically significant change in CD4+ % (P = 0.111) or count (P = 0.165) was found over time ( Figure 1 ).
Associations Between Treg cell/CD4+ Measures and Clinical Response
No statistically significant associations were found between Treg cell/CD4+ counts or % and a skin disease score reduction of 25% or greater, or the ability to taper steroids by 50% or greater.
Differences in the Distribution of Treg cells/CD4+ Between Responders and Nonresponders
Skin Response
At 28 weeks, patients demonstrating a skin response had statistically significantly different distributions of Treg cell counts at 3 months post-ECP (P = 0.025), with a higher median, than nonresponders (7.7 vs 3.1 cells/μL) (Figure 2) . Skin responders at 56 weeks had lower medians than nonresponders (P ≤ 0.044), of: CD4 + % at 0-9 months post-ECP ( Figure S1 , SDC, http://links.lww.com/TP/B255); and CD4+ counts at 1 and 9 months ( Figure S2 , SDC, http://links.lww. com/TP/B255).
Steroid Response
Patients demonstrating a steroid response at 56 weeks had higher median counts of Treg cells (P = 0.009) (Figure 2 ) and CD4+ (P = 0.027) ( Figure S2 , SDC, http://links.lww.com/TP/B255) at 12 months post-ECP.
Global Organ Response
At 28 weeks, patients demonstrating a reduction in global organ involvement had statistically significantly different distributions, with higher medians, of Treg cell counts at 3 months post-ECP than nonresponders (P = 0.023) (Figure 2 ), but similar Treg cell % ( Figure S3 , SDC, http://links.lww.com/TP/B255). At 56 weeks, responders had lower median: CD4+ % at 0 to 2 and 6 months (P ≤ 0.044) ( Figure S1 , SDC, http://links.lww.com/TP/B255); 
Skin Response
No association was found between post-ECP changes in Treg cell or CD4+ measures and an improvement in skin disease of ≥25%.
Steroid Response
No association was found between post-ECP changes in Treg cell measures and the ability to taper steroids. For the CD4+ analyses, after controlling for pre-ECP CD4+ count and platelet count, a 1 cell/μL increase in the difference between pre-ECP and 1, 2, and 3 months CD4+ counts increased the odds of a steroid response at 14 weeks (1 month: odds ratio [OR], 1.0067; 95% confidence interval [95% CI], 1.0002-1.0132; P = 0.043; 2 months: OR, 1.0100; 95% CI, 1.0002-1.0198; P = 0.045; 3 months: OR, 1.009; 95% CI, 1.001-1.016; P = 0.027). Similar results were found for 3 months CD4+ counts with cyclosporine as a covariate (OR, 1.008; 95% CI, 1.001-1.016; P = 0.028).
Associations Between Treg Cell/CD4+ Measures and Skin Scores
Moderate positive associations were observed between pre-ECP Treg cell counts and baseline skin scores (higher Treg cell counts associated with greater skin disease) (P = 0.025) ( Figure S4a , SDC, http://links.lww.com/TP/B255) or 14 weeks (P = 0.034). Moderate positive associations were also seen between skin scores at 56 weeks and CD4+ % at pre-ECP (P = 0.042), 1 month (P = 0.019), 2 months (P = 0.036), 3 months (P = 0.008), 6 months (P = 0.006), and 9 months (P = 0.008), and CD4+ counts at 1 month (P = 0.047) and 9 months (P = 0.023).
Associations Between Treg Cell/CD4+ Measures and Steroid Dose
Lower Treg cell counts at 12 months were associated with higher steroid dose at 56 weeks and, therefore, greater disease activity (negative association, P = 0.009) ( Figure S5a , SDC, http://links.lww.com/TP/B255). A higher pre-ECP Treg cell %, however, was positively associated with greater baseline steroid dose (P = 0.016) ( Figure S5b , SDC, http://links. lww.com/TP/B255), whereas lower pre-ECP CD4+ counts were associated with greater baseline steroid dose (P = 0.003). Similarly, lower 3 months CD4+ counts were associated with higher 14 weeks steroid dose (negative association, P = 0.033) ( Figure S5c , SDC, http://links.lww.com/TP/B255). 
DISCUSSION
Our study of 32 cGvHD patients treated with ECP revealed a statistically significant increase in Treg cells from baseline at 6 months post-ECP and beyond, which is at variance with some previous reports. Rao and colleagues, 21 for example, did not find a statistically significant difference in Treg cells in 11 cGvHD patients for their study duration of 0 to 6 months post-ECP. Our results also conflict with the study of 27 cGvHD patients by Di Biaso and colleagues, 22 who reported a statistically significant increase in Treg cells at the 6th ECP cycle (approximately 3 months post-ECP), but not thereafter. Their study also found that only cGvHD patients who responded to ECP demonstrated an increase in circulating Treg cell numbers, whereas we found no clear pattern, with some nonresponders showing an increase in numbers and/or proportion of Treg cells, and some responders whose Treg cell counts decreased or remained static.
We conducted a high number of tests that led to the issue of multiple testing. Caution should be applied when interpreting results because the more tests performed, the more likely it is to obtain a false-positive result.
Interestingly, no statistically significant increase in median CD4+ T-cell count or % was found, even after 12 months of ECP ( Figure 1E-H) . Both pre-and post-ECP CD4+ counts were statistically significantly lower in cGvHD patients compared with healthy controls. Our study indicates that ECP did not normalize CD4+ T-cell numbers, which conflicts with the findings of Bladon and Taylor, 23 who found an enhancement of CD4+ T-cell numbers after 3 months of ECP in their study of 8 cGvHD patients.
The functionality of Treg cells was not tested in our study, and it is important to consider that the Treg cells we measured may be dysfunctional or possess an elevated suppressive quality, thereby affecting their potential to influence immune responses in a greater or lesser capacity. Indeed, ECP has been shown to augment immunosuppressive Treg cell function by triggering CD39-mediated adenosine production by Treg cell, which can reduce T-cell proliferation. 24 Regulatory T cells can, therefore, become more suppressive after ECP, but augmentation of adenosine production is only 1 of a number of mechanisms that operate during Treg cell-mediated suppression. The variety of impairment that may occur in cGvHD of other suppressive mechanisms, such as: the release of IL-10 and/or TGF-β; consumption of IL-2; and the expression of inhibitory molecules, 16 may account somewhat for our heterogeneous observations that patients with low or high Treg cell counts or % demonstrated a clinical response.
Our analysis of Treg cell numbers and proportion in cGvHD patients has shown a high degree of variability. A heterogeneous study population complicates the interpretation of results, with Treg cell reconstitution and clinical response being influenced by patient characteristics, stem cell source, T-cell depletion strategy of the graft, infections, underlying disease, extent of tissue injury, and immunosuppressive medications. 25 Changes in Treg cell frequencies can be either drug-induced, or disease-related, and it is important to remember that drug use varies as ECP progresses. Intravenous immunoglobulin expands Treg cells, 26 calcineurin inhibitors used to treat GvHD decrease Treg cell numbers, whereas sirolimus use produces an increase, and corticosteroids are known to enhance expression of FOXP3 and improve the survival and function of Treg cells. 27 The cytokine milieu in which Treg cells operate can also affect their function. For example, TNF downmodulates the function of CD4 + CD25+ Treg cells, 28 and TGF-β induces FOXP3 expression. 29 In an attempt to resolve the debate as to the importance of Treg cells in clinical response to ECP, we not only looked at associations of response with Treg cell counts and %, but also investigated if it was the change in Treg cell measures post-ECP that might be pivotal. Furthermore, associations between Treg cell measures and skin and steroid scores were examined. From all these analyses, the conclusion of no clear associations between Treg cell measures and clinical improvement is drawn. Consistent with our findings, Nord et al 30 found in her study of 16 cGvHD patients, who were treated with ECP for a minimum of 3 months, that increases in the proportion of Treg cells were not always accompanied by clinical benefit. Any significant impact of Treg cells on the clinical improvement of patients with cGvHD after ECP may be qualitative rather than quantitative, rendering observations based solely on the quantity of Treg cells of limited use. Furthermore, if there is no deficit of Treg cells in cGvHD, as several studies have suggested, 12, 13 it is unlikely that simply boosting PB Treg cell numbers will be sufficient to generate complete amelioration. A better understanding of the diversity of Treg cell subsets, plasticity, and function in the context of ECP therapy and cGvHD is required, with a greater focus on their role in target organs. A greater force than PB Treg cells alone is likely to be needed to suppress the chronic inflammatory process at work in cGvHD, involving cellular and humoral responses, cytokines, and chemokine expression in target tissues.
